PharmaBlock buys plant in China from Porton Pharma

Nanjing, China-based PharmaBlock has acquired a manufacturing site from Porton Pharma Solutions in Shangyu, China. (PharmaBlock)

China’s PharmaBlock Sciences says it has acquired a GMP-compliant manufacturing facility from Porton Pharma Solutions in Shangyu, China, where it will make intermediates.

The 1,436,000-square-foot site, located in a state-level chemical industry park in Shangyu, Zhejiang Province, has been operating as a multipurpose, GMP-compliant facility since December 2015, according to a press release. Terms of the deal were not disclosed.

The facility is equipped with reactors with 300 L to 6300 L in capacity and can handle a range of chemistry synthesis and enabling processes, PharmaBlock said. The Chinese firm intends to begin construction on a second phase this year which will allow it to manufacture APIs at the site.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“The acquisition of this site provides additional GMP capacity and supplements our existing assets in Shandong Dezhou site,” PharmaBlock chairman Minmin Yang said in a statement.

The release said that PharmaBlock also has a new process R&D center outside of Philadelphia, Pennsylvania. It said phase I at the 7,000-square-foot facility is now in full operation.


Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.